Registrations for this event are now closed.
A cancer diagnosis has profound and enduring effects on individuals and extends its impact to loved ones, colleagues, communities, and across society.
In September 2022, Rare Cancers Australia (RCA) and Canteen launched a report Counting the cost: the true value of investing in cancer treatment. The report explored what matters most to people receiving cancer treatments, in terms of the social and personal impacts, and put a value on those benefits through Social Return on Investment analysis.
Report launch
One year on, we are pleased to be launching Counting the cost: how we can assess the true value of investing in cancer treatment, which provides a practical case study demonstrating how we can effectively integrate social value within our health technology assessments.
View report
An initiative of RCA and Canteen
Counting the cost: how we can assess the true value of investing in cancer treatment
One year on, we are pleased to be launching Counting the cost: how we can assess the true value of investing in cancer treatment, which provides a practical case study demonstrating how we can effectively integrate social value within our health technology assessments.
Please join us as we launch the latest report, when we will move the discussion from 'why' we should incorporate social value in our health technology assessments to 'how' we can accomplish it.
Facilitator
Speakers
An initiative of RCA and Canteen
Register
Questions
Please contact Nikki Kerr, Head of Partnerships, at nikki@rarecancers.org.au
Report Sponsors
Rare Cancers Australia would like to acknowledge our supporters who help make the production of this report possible: